Agilent Technologies, Inc. (A)

FairStock Score: 60/100 — STEADY

Key Financials

Strengths

• Strong competitive moat in life sciences instrumentation with high customer switching costs
• Excellent Q1 2026 net margin of 16.96% demonstrating pricing power
• Solid free cash flow generation of $855.9M annually
• Diversified end-markets across life sciences, diagnostics, and applied markets
• Healthy balance sheet with D/E ratio of 0.51

Concerns

• Valuation is egregiously expensive: P/B of 4.55 and EV/EBITDA of 74.87 with a -372% margin of safety
• Poor FCF yield of 0.5% suggests market is pricing in unrealistic growth
• ROCE of 8.53% substantially below cost of capital, indicating value-destructive capital deployment
• Piotroski F-Score of 5/9 signals mixed financial health and operational trends
• Stock trading near 52-week highs at $115.07 (vs. $96 low) with heightened downside risk

AI Analysis

Looking at Agilent, I see a business with genuine competitive advantages in life sciences instrumentation and diagnostics—markets with durable demand and high switching costs. The 16.96% net margin in Q1 2026 and $855.9M in free cash flow demonstrate real earning power. However, I must be candid: this company is significantly overvalued at current prices. At $115.07, the stock trades at 4.7x book value and sports an EV/EBITDA of 74.87—multiples I find difficult to justify even for quality businesses. The Graham Number of $24.37 suggests an intrinsic value less than one-fifth the current price, implying a negative margin of safety of over 370%. The Piotroski F-Score of 5/9 is mediocre, and the FCF yield of just 0.5% indicates I'd be paying $200 of market cap for every dollar of free cash generated annually. The ROE of 19.95% is attractive, but the ROCE of only 8.53% suggests capital allocation challenges. While the diagnostics and life sciences markets offer structural growth, particularly in genomics and contract manufacturing, I cannot recommend Agilent at these valuations. The market has priced in perfection. I prefer to fish where the odds favor the angler—and Agilent's risk-reward here is decidedly unfavorable.

Bull Case

Agilent operates in secular growth markets (genomics, diagnostics, life sciences research) with durable competitive advantages and recurring revenue streams. Strong 16.96% margins and $855.9M FCF generation could support continued shareholder returns if the company accelerates capital returns and maintains operational discipline.

Bear Case

The stock's valuation has completely disconnected from intrinsic value—the Graham Number suggests the stock is worth 79% less than current prices. If growth disappoints or rates remain elevated, multiple compression could be severe, and the poor ROCE suggests capital isn't being deployed effectively for shareholders.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer